# Atypical Antipsychotics

This is a subcategory of Central Nervous System (CNS) Agents.

## Formulary

### Preferred

| Preferred            |
| :------------------- |
| Abilify Maintena     |
| Aripiprazole         |
| Aristada             |
| Aristada Initio      |
| Clozapine            |
| Fanapt ST            |
| Geodon               |
| Invega BvG           |
| Invega Hafyera ER PA |
| Invega Sustenna      |
| Invega Trinza        |
| Latuda ST            |
| Olanzapine           |
| Perseris             |
| Quetiapine           |
| Quetiapine ER        |
| Risperdal            |
| Risperdal Consta     |
| Risperidone          |
| Saphris BvG ST       |
| Ziprasidone          |

### Non-Preferred

| Non-Preferred         |
| :-------------------- |
| Abilify Mycite        |
| Aripiprazole Sol      |
| Asenapine             |
| Caplyta               |
| Clozapine ODT Rapdis  |
| Fluoxetine/Olanzapine |
| Lybalvi               |
| Nuplazid              |
| Olanzapine ODT        |
| Paliperidone          |
| Rexulti               |
| Secuado               |
| Versacloz             |
| Vraylar               |
| Zyprexa Relprevv      |

## Length of Authorizations

365 Days

## Grandfathering

Patients who have a claim for a non-preferred drug, or drug requiring step therapy, in the previous 120 days will be automatically approved to continue the drug. Patients who have taken the drug in the previously but do not have claims history (e.g. new to Medicaid), will need to submit a prior authorization in order to continue coverage.

## Prior Authorization Criteria

Is there any reason the patient cannot be changed to a medication not requiring prior approval?

Acceptable reasons include:

-   Allergy to all medications not requiring prior approval
-   Contraindication to or drug-to-drug interaction with medications not requiring prior approval.
-   History of unacceptable/toxic side effects to medications not requiring prior approval

### Psychiatrist Exemption

Providers (as identified below) are exempt from prior authorization of any non-preferred second-generation antipsychotic, or step therapy of any preferred brand, in the standard tablet/capsule dosage forms. Other dosage forms may still require prior authorization. The exemption will be processed by the claims system when the pharmacy has submitted the prescriber on the claim using the individual national provider identifier (NPI) for the provider.

**FFS**: Physicians who are registered with Ohio Medicaid as having a specialty in psychiatry

**MCOs**: Physicians with a specialty in psychiatry, nurse practitioners certified in psychiatric mental health, or clinical nurse specialists certified in psychiatric mental health, who are credentialed via the Medicaid managed care plan

## Additional Criteria

### Step Therapy

Step Therapy Approval Criteria

1.  For a drug requiring step therapy, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than **30 days** of at least **one preferred** product
2.  For a non-preferred drug, there must have been inadequate clinical response to preferred alternatives, including a trial of no less than **30 days each** of at least **two preferred** or step therapy products

### Other

Other Approval Criteria

Is there any reason the patient cannot be changed to a preferred medication?

Acceptable reasons include:

-   Allergy to preferred medications
-   Contraindication to or drug interaction with preferred medications
-   History of unacceptable/toxic side effects to preferred medications
-   For orally disintegrating tablet dosage forms, the patient is unable or unwilling to swallow the standard tablet/capsule dosage form.
-   The requested medication’s corresponding generic (if covered by the state) has been attempted and failed or is contraindicated.
-   Lurasidone (pregnancy category B) may be approved if a patient is pregnant
-   Abilify Mycite will be restricted to prescribing by a psychiatrist following an aripiprazole serum blood level draw indicating need for further investigation of adherence.

#### Antipsychotics, Second Generation And SSRI Combination

| **No PA Required "Preferred"** | **Step Therapy Required "Preferred"** | **PA Required "Non-Preferred"** |
| ------------------------------ | ------------------------------------- | ------------------------------- |
|                                | A trial of no less than 30 days each of at least two preferred second- generation oral antipsychotics or step therapy products | FLUOXETINE/OLANZAPINE (generic of Symbyax®) |

\+ Long-Acting Injectable Antipsychotics may be billed by the pharmacy if they are not dispensed directly to the patient. If not administered by the pharmacist, the drug must be released only to the administering provider or administering provider's staff, following all regulations for a Prescription Pick-Up Station as described by the Ohio Board of Pharmacy.

### Invega Hafyera ER

Additional Criteria for Invega Hafyera ER

1.  Treatment with 4 months of Invega Sustenna or 3 months of Invega Trinza before starting Invega Hafyera.

### Lybalvi

Additonal Criteria for Lybalvi

1.  Patient must not be using opioids.
2.  Patient must not be undergoing acute opioid withdrawal.

### Parkinson's Disease Psychosis (Nuplazid)

Additional Criteria for Agents for Parkinson's Disease Psychosis (Nuplazid)

Pimavanserin (Nuplazid) may be approved if all the following are met:

1.  Patient is diagnosed with Parkinson’s disease and has psychotic symptoms (hallucinations and/or delusions) that started after Parkinson’s diagnosis
2.  These psychotic symptoms are severe and frequent enough to warrant treatment with an antipsychotic AND are not related to dementia or delirium
3.  The patient’s other medications for Parkinson’s Disease have been reduce or adjusted and psychotic symptoms remain OR patient is unable to tolerate adjustment of these other medications
4.  There has been inadequate clinical response to a trial of no less than **30 days** of either quetiapine or clozapine OR these therapies cannot be utilized
5.  An exemption to the criteria will be granted for prescribing doctors with a neurology specialty to a patient with a history of an anti-Parkinson’s agent

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_Criteria_APPROVED.pdf#page=32)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_APPROVED_.pdf#page=15)
